A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission

European Journal of Gynaecological Oncology

Volumn 29, Issue 6, 2008, Pages 568-572

  Juretzka, M ^a   Hensley, M L ^a   Tew, W ^a   Konner, J ^a   Aghajanian, C ^a   Leitao, M ^a   Iasonos, A ^a   Soslow, R ^a   Park, K ^a   Sabbatini, P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Imatinib; Ovarian cancer; Peritoneal; Remission

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG WITHDRAWAL; DRY EYE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PETECHIA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; URETER STONE; UTERINE TUBE CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 56749138439     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oncol., 2003, 21, 3194.
2. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S. et al.: "Intraperitoneal cisplatin and paclitaxel in ovarian cancer". N. Engl. J. Med., 2006, 354, 34.
3. Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G. et al.: "Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design". J. Clin. Oncol., 2004, 22, 3120.
4. Westermark B., Heldin C.H.: "Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth". Acta Oncol., 1993, 32, 101.
5. Dabrow M.B., Francesco M.R., McBrearty F.X., Caradonna S.: "The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium". Gynecol. Oncol., 1998, 71, 29.
6. Sariban E., Sitaras N.M., Antoniades H.N., Kufe D.W., Pantazis P.: "Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines". J. Clin. Invest., 1988, 82, 1157.
7. Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., Oberg K.: "Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms". Cancer Res., 1993, 53, 4550.
8. Versnel M.A., Haarbrink M., Langerak A.W., de Laat P.A., Hagemeijer A., van der Kwast T.H. et al.: "Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo". Cancer Genet. Cytogenet., 1994, 73, 60.
9. Schmandt R.E., Broaddus R., Lu K.H., Shvartsman H., Thornton A., Malpica A. et al.: "Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium". Cancer, 2003, 98, 758.
10. Rustin G.J., Nelstrop A.E., Bentzen S.M., Piccart M.J., Bertelsen K.: "Use of tumour markers in monitoring the course of ovarian cancer". Ann. Oncol., 1999, 10, 21.
11. Apte SM., Fan D., Killion J.J., Fidler J.J.: "Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma". Clin. Cancer Res., 2004, 10, 897.
12. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M. et al.: "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome". N. Engl. J. Med., 2001, 344, 1038.
13. Coleman R.L., Broaddus R.R., Bodurka D.C., Wolf J.K., Burke T.W., Kavanagh J.J. et al.: "Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers". Gynecol. Oncol., 2006, 101, 126.
14. Alberts D.S., Liu P.Y., Wilczynski S.P., Jang A., Moon J., Ward J.H. et al.: "Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)". Int. J. Gynecol. Cancer, 2007.
15. Panageas K.S., Ben-Porat L., Dickler M.N., Chapman P.B., Schrag D.: "When you look matters: the effect of assessment schedule on progression-free survival". J. Natl. Cancer Inst., 2007, 99, 428.
16. Bristow R.E., Lagasse L.D., Karlan B.Y.: "Secondary surgical cytoreduction for advanced epithelial ovarian cancer". Cancer, 1996, 78, 2049.
17. Leitao M.M. Jr., Kardos S., Barakat R.R., Chi D.S.: "Tertiary cytoreduction in patients with recurrent ovarian carcinoma". Gynecol. Oncol., 2004, 95, 181.
18. McCreath W.A., Chi D.S.: "Surgical cytoreduction in ovarian cancer". Oncology (Williston Park), 2004, 18, 645.